1. Home
  2. MAIA vs HHS Comparison

MAIA vs HHS Comparison

Compare MAIA & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • HHS
  • Stock Information
  • Founded
  • MAIA 2018
  • HHS 1923
  • Country
  • MAIA United States
  • HHS United States
  • Employees
  • MAIA N/A
  • HHS N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • HHS Advertising
  • Sector
  • MAIA Health Care
  • HHS Consumer Discretionary
  • Exchange
  • MAIA Nasdaq
  • HHS Nasdaq
  • Market Cap
  • MAIA 52.7M
  • HHS 52.3M
  • IPO Year
  • MAIA 2022
  • HHS N/A
  • Fundamental
  • Price
  • MAIA $2.00
  • HHS $5.38
  • Analyst Decision
  • MAIA
  • HHS
  • Analyst Count
  • MAIA 0
  • HHS 0
  • Target Price
  • MAIA N/A
  • HHS N/A
  • AVG Volume (30 Days)
  • MAIA 233.1K
  • HHS 23.6K
  • Earning Date
  • MAIA 11-12-2024
  • HHS 11-14-2024
  • Dividend Yield
  • MAIA N/A
  • HHS N/A
  • EPS Growth
  • MAIA N/A
  • HHS N/A
  • EPS
  • MAIA N/A
  • HHS N/A
  • Revenue
  • MAIA N/A
  • HHS $187,604,000.00
  • Revenue This Year
  • MAIA N/A
  • HHS N/A
  • Revenue Next Year
  • MAIA N/A
  • HHS $4.05
  • P/E Ratio
  • MAIA N/A
  • HHS N/A
  • Revenue Growth
  • MAIA N/A
  • HHS N/A
  • 52 Week Low
  • MAIA $0.95
  • HHS $5.31
  • 52 Week High
  • MAIA $5.99
  • HHS $8.87
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 40.60
  • HHS 32.48
  • Support Level
  • MAIA $1.93
  • HHS $5.73
  • Resistance Level
  • MAIA $2.63
  • HHS $5.98
  • Average True Range (ATR)
  • MAIA 0.21
  • HHS 0.28
  • MACD
  • MAIA 0.02
  • HHS 0.02
  • Stochastic Oscillator
  • MAIA 21.22
  • HHS 7.87

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

About HHS Harte-Hanks Inc.

Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.

Share on Social Networks: